Immune Modulator Drugs Improved Survival for People Hospitalized with COVID-19

COVID-19 molecules
Image Credit: Fernando Da Cunha/Science Photo Library

Preliminary results from ACTIV-1 Immune Modulator clinical trial show immune modulator drugs, infliximab and abatacept, substantially improved clinical status and reduced deaths in adults hospitalized with COVID-19. NIH launched this trial to evaluate safety and efficacy of three immune modulator drugs. The trial was coordinated and overseen by NCATS. NCATS’ CTSA Program and Trial Innovation Network played a key role in enrolling participants.

Learn More